Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.
Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong RC, Du Y, Wang B, Authement C, Hernandez E, Yang J, Xiao G, Cha TL, Wu HC, Wu D, Margulis V, Lotan Y, Brugarolas J, He D, Hsieh JT.
Zhou J, et al.
Oncogene. 2016 Sep 1;35(35):4663-74. doi: 10.1038/onc.2016.4. Epub 2016 Feb 15.
Oncogene. 2016.
PMID: 26876207